You are here:
Home /
News / FDA Warns of Risk of Eosinophilic Pneumonia with Daptomycin
FDA Warns of Risk of Eosinophilic Pneumonia with Daptomycin
Washington, DC: The FDA has notified healthcare professionals and patients about the potential for developing eosinophilic pneumonia during treatment with Cubicin (daptomycin), an intravenous antibacterial drug indicated for use in treatment of serious skin infections and bloodstream infections.